Hypochondroplasia clinical trials at UCSF
3 in progress, 2 open to eligible people
Hypochondroplasia is a genetic disorder that affects bone growth. UCSF is conducting studies to track how children with this condition grow over time. Researchers are gathering detailed measurements of children's growth and health in these observational studies.
Multinational Observational Study of Children With Hypochondroplasia
open to eligible people ages up to 15 years
This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
Oakland, California and other locations
Clinical Assessment Study in Children With Hypochondroplasia
open to eligible people ages 30 months to 16 years
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
Oakland, California and other locations
Interventional Study of Infigratinib in Children With Hypochondroplasia
Sorry, accepting new patients by invitation only
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety, of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib, at one of two doses, of who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).
Oakland, California and other locations
Last updated: